EUVIMEDEUVIMED entdecken
Open Access

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays

Masahiro Takeyama, Yasuharu Nishida, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami

Haemophilia · 2026

DOI: 10.1111/hae.70341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Masahiro Takeyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemophilia, National Hospital Organization Osaka National Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Hemostasis, Blood Coagulation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Efanesoctocog alfa (Efa) is a high‐sustained factor (F)VIII engineered to overcome von Willebrand factor (VWF)‐dependent clearance, enabling once‐weekly dosing. However, FVIII activity (FVIII:C) differs between the one‐stage assay (OSA) and chromogenic substrate assay (CSA), and its relationship with global assays remains unclear.

Aim

To assess the procoagulant potential in people with haemophilia A (PwHA) treated with Efa using conventional and global assays.

Methods

Plasma samples were collected from five PwHA treated with Efa. FVIII:C was assayed using OSA (RevohemAPTT, PathromtinSL at two institutions) and CSA. Clot waveform analysis (CWA) using RevohemAPTT SLA and ThromboCheck APTT SLA, thrombin generation assay (TGA), and rotational thromboelastometry were performed. Apparent equivalent FVIII:C (app‐eq‐FVIII:C) was derived from reference curves for cross‐assay comparison.

Results

OSA‐FVIII:C showed reagent‐ and site‐dependent variability. Pathromtin‐based FVIII:C aligned with Revohem‐based values at one site but was 1.6–1.8‐fold higher at the other. CSA values were higher; CSA/2.5 variably approximated OSA in this dataset. CWA increased consistently after administration, with Revohem‐based assays higher than ThromboCheck‐based assays, indicating reagent‐dependent variation within CWA. TGA showed increased thrombin generation with interpatient variability, ranging from minimal to relatively marked increases; conversion to app‐eq‐FVIII:C was strongly parameter‐dependent (time‐to‐Peak vs Peak‐Th). Rotational thromboelastometry revealed heterogeneous responses, and app‐eq‐FVIII:C was frequently lower than OSA and CSA/2.5‐derived values.

Conclusion

Efa demonstrated assay‐detected post‐infusion increases; however, FVIII:C measurement varied across platforms and parameters. In this small exploratory cohort, these findings support assay‐specific validation and cautious interpretation of inter‐platform differences, rather than definitive conclusions regarding optimal monitoring strategy or direct clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHemostasisBlood CoagulationHumansBlood Coagulation Tests

Stichwörter der Autor:innen

Haemophilia Achromogenic substrate assayefanesoctocog alfaglobal hemostatic assaysone‐stage assay

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Division of Hemophilia, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.

Zitieren

APA

Takeyama, M., Nishida, Y., Furukawa, S., Ogiwara, K., & Nogami, K. (2026). Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays. Haemophilia. https://doi.org/10.1111/hae.70341

Vancouver

Takeyama M, Nishida Y, Furukawa S, Ogiwara K, Nogami K. Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays. Haemophilia. 2026. doi:10.1111/hae.70341

BibTeX
@article{Takeyama2026,
  author = {Takeyama, Masahiro and Nishida, Yasuharu and Furukawa, Shoko and Ogiwara, Kenichi and Nogami, Keiji},
  title = {Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70341}
}
Kostenlos starten →